8-K filed May 15, 2026
Dexcom authorizes $1B for stock buybacks
“On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”).”
From Dexcom’s 8-K filed May 15, 2026 · read the filing · all documents
How big is it?
Dexcom bought back $1.1B of stock in the twelve months to Jun 30, 2026. At that pace, $1.0B covers about 11 months of buybacks.
The amount equals 71% of its free cash flow over the same twelve months ($1.4B).
Its diluted share count is down 4.4% from a year earlier.
An authorization is permission, not a promise: the company can buy less, more slowly, or not at all, and usually doesn't have to say when it buys.
Show as table
| Period | Value |
|---|---|
| Q3 '23 | $0 |
| Q4 '23 | $0 |
| Q1 '24 | $0 |
| Q2 '24 | $0 |
| Q3 '24 | $749.5M |
| Q4 '24 | $0 |
| Q1 '25 | $0 |
| Q2 '25 | $0 |
| Q3 '25 | $187.7M |
| Q4 '25 | $315.9M |
| Q1 '26 | $0 |
| Q2 '26 | $605.6M |